Scientists to trial rheumatoid arthritis drug in ICU patients with COVID-19

Published:

Queensland researchers are preparing to begin a clinical trial of a drug that regulates inflammation in the hope it may help save the lives of critically ill patients with COVID-19.

The immunoregulatory drug Tocilizumab* is used to treat rheumatoid arthritis and some other inflammatory conditions.

The drug works by blocking an immune system molecule called IL6, which causes inflammation, and is thought to contribute to the severe respiratory failure that can occur in the second week of the COVID-19 illness.  Australia’s Therapeutic Goods Administration approved its use in patients with rheumatoid arthritis in 2009.

The trial is being led by QIMR Berghofer Associate Professor Bridget Barber, who is also an infectious diseases physician at the Royal Brisbane and Women’s Hospital.

Associate Professor Barber said high levels of the inflammatory molecule IL6 have been detected in critically ill COVID-19 patients.

“Intensive care units around the world have reported that many patients deteriorate about a week after they experience the first symptoms of COVID-19,” Associate Professor Barber said.

“Other studies have shown an increase in the patients’ inflammatory response around that time, including high levels of IL6.

“We think it’s this inflammatory response – caused by some parts of the immune system over-reacting to the virus – that is making these patients so unwell.

“We hope that Tocilizumab will improve outcomes in critically ill patients by blocking this key inflammatory molecule IL-6, and preventing some of the damage that is caused by this inflammatory response.”

Associate Professor Barber said a small, observational study of the drug in Italy had shown some promising early results, but more research was needed.

“We will be conducting a randomised control trial of the drug, which is the only way of knowing whether or not it is effective,” she said.

“Two thirds of the patients we recruit will be given Tocilizumab and their responses will be monitored and compared to the one third of patients who will not get the treatment.

“It is only through these rigorous clinical trials that we can see whether or not different treatments improve clinical outcomes and survival.”

The trial will initially involve intensive care patients from the Royal Brisbane and Women’s Hospital and other Metro North sites such as the Redcliffe Hospital.

“Fortunately, Australia has seen a big fall in COVID-19 cases; however, we do expect that a small number of patients will continue to become infected and will require admission to ICU,” Associate Professor Barber said.

“More importantly, we need to be prepared for the possibility that cases may increase again at a later stage. If Australia does see an increase in cases in the coming months, the trial will be available to critically ill patients at participating hospitals.

“There are a number of other randomised controlled trials around the world also evaluating Tocilizumab, however, until we know the results we think it’s important to proceed with this trial in Brisbane.

“It will enable critically ill patients in participating hospitals to be enrolled in the clinical trial, with two-thirds of participants given Tocilizumab.”

Associate Professor Barber is collaborating with expert immunologists at QIMR Berghofer, including the head of the Institute’s Immunology and Infection group, Professor Christian Engwerda, so that the effect of Tocilizumab on patients’ immune systems can be studied.

“If we do find that the drug is effective, this collaboration will allow us to better understand how the drug is working,” she said.

Associate Professor Barber said it was important to evaluate existing drugs because they could be offered to vulnerable patients relatively quickly.

“Tocilizumab has already gone through regulatory approvals and we know the side effects it could pose, so it is relatively straight-forward to evaluate it in a clinical trial to see if it will improve outcomes and reduce the risk of death in patients with COVID-19,” she said.

The trial has been submitted for approval to the Royal Brisbane and Women’s Hospital Ethics committee, and once the trial has commenced, patients will only be enrolled when they or their families give permission.

The trial is being funded by philanthropic donations to QIMR Berghofer, including from Clive Berghofer AM and the Brazil Family Foundation.

*Pronounced: tok-uh-LIZ-uh-mab

 
Coronavirus COVID-19 Health & Wellness Science & Research
Social:   

QIMR Berghofer Medical Research Institute :
PO Royal Brisbane Hospital, Brisbane, QLD, 4029, Brisbane
07 3845 3752
QIMR Berghofer Medical Research Institute
Showing 10+ recent articles for this business
Researchers get a better grip on left and right handedness 29 September 2020 | In the largest study of its kind to date, researchers have identified 48 genetic variants that influence if a person is left-handed, right-handed or ambidextrous. More information...
New potential weapon found in battle against cancer and inflammatory diseases 24 August 2020 | QIMR Berghofer-led research has discovered the pivotal role played by an important immune system protein that, if harnessed through immunotherapy, has the potential to treat a wide range of cancers and inflamma... More information...
Brain cancer clinical trial gives hope to patients 13 August 2020 | Queensland researchers have found that patients who received a cellular immunotherapy for the deadly brain cancer glioblastoma multiforme (GBM) in a clinical trial on average survived longer than would have been... More information...
Pessimistic outlook on life linked to life expectancy 29 July 2020 | A new QIMR Berghofer Medical Research Institute study has found people who are strongly pessimistic about the future are at greater risk of dying earlier than those who are not pessimists. More information...
New keys found for unlocking head and neck cancer treatment 28 July 2020 | QIMR Berghofer scientists say the discovery of new cellular immunotherapy targets for a deadly type of head and neck cancer, caused by human papillomavirus (HPV), could lead to better survival rates. More information...
Scientists identify new target for melanoma immunotherapy 30 June 2020 | QIMR Berghofer research has found a new reason why some melanoma patients do not respond well to immunotherapy – a discovery that could lead to better-tailored treatments for the potentially deadly cancer. More information...
Heart research to be revolutionised thanks to $8 million funding boost 25 June 2020 | Queensland researchers will begin developing a comprehensive ‘encyclopedia’ of the heart in a world-first project that, if successful, will revolutionise cardiac research and treatment. More information...
Researchers stimulate improvements in Parkinson's treatment 23 June 2020 | New research led by QIMR Berghofer Medical Research Institute has identified ways to make the most widely-used advanced treatment for Parkinson’s disease – deep brain stimulation therapy – more effective and... More information...
Blood cancer find raises new treatment hopes 16 June 2020 | New QIMR Berghofer research has identified how an early genetic change in blood and bone marrow cells paves the way for the development of some blood cancers. More information...
New evidence of dangers of high-fat diet on pre-cancerous condition 08 June 2020 | New QIMR Berghofer research indicates that a high-fat diet over a long period of time may induce early Barrett’s oesophagus, a precursor condition to oesophageal cancer. More information...


comments powered by Disqus

All articles submitted by third parties or written by My Sunshine Coast come under our Disclaimer / Terms of Service